NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Market By Therapeutics & Diagnostics And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

North America Alzheimer’s disease therapeutics and diagnostics market is expected to rise at a CAGR of 7.58% in terms of revenue during the estimated period of 2019-2027.

The key countries covered in North America Alzheimer’s disease therapeutics and diagnostics market are:

•      The United States

•      Canada

Alzheimer’s is one of the leading causes of death in the North America region. It is an asymptomatic disease that causes problems like degradation of memory, inability to think properly and erratic behavioral changes. From the treatment context, very few therapeutic alternative techniques are available in the market, and none of them are accurate enough to provide the best-personalized drug diagnostics based on the stage, symptoms and various demographics of the patient. Added to this, the lack of trained professionals and training centers for the diseases indicates an upcoming market demand and a progressive growth potential in these regions for the Alzheimer’s disease therapeutics and diagnostics market.

As the size and proportion of the United States’ population aged 65 and older continue to increase, the number of Alzheimer’s cases are increasing rapidly. ‘Alzheimer’s Initiative’ started by former president Barak Obama in 2011 has shown significant improvements in the drug development and medical services in the US. In Canada, the number of Alzheimer’s cases has been anticipated to increase by xx% by 2031. The high costs of treatments have taken a toll on the common man living in the North American region. But the improvements in the health awareness initiatives, higher education with respect to trained professionals and various research programs are paving the way for a profitable market for the companies operating in the market.

The North America-based Amarantus BioScience Holdings, Inc. is a headquartered in California. It is a biopharmaceutical company involved in developing therapeutic and diagnostic products. The company is focusing on developing and commercializing neurology diagnostic products; it developed “LymPro Test,” which is a blood-based assay for the diagnosis of Alzheimer’s disease. Established in 2008 as Amarantus Bioscience, Inc., the company changed its name to Amarantus BioScience Holdings, Inc. in 2013.


The top key players in the Alzheimer’s disease therapeutics and diagnostics market include AbbVie, Amarantus BioScience Holdings Inc., AXON Neuroscience SE, Baxter, Biogen, Cognoptix, DiaGenic ASA, Roche, GE Healthcare, Merck, Johnson & Johnson, Piramal Enterprises Ltd., Siemens Healthineers AG, and Sun Pharmaceutical Industries Ltd.


Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. KEY FINDINGS

2.8. INDUSTRY STRUCTURE

2.8.1. RESEARCH AND DEVELOPMENT

2.8.2. MANUFACTURING

2.8.3. RAW MATERIALS

2.8.4. END USER

2.8.5. WHOLESALERS

2.9. REGULATORY FRAMEWORK

2.10. THE UNITED STATES AND EUROPE REGULATORY AGENCY

2.11. ALZHEIMER'S DISEASE ETIOLOGY

2.12. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF THE ALZHEIMER’S DISEASE

2.13.2. GROWING GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. THE TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. AWARENESS IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE

3.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.3. PRODROMAL STAGE

3.1.4. THERAPEUTICS BY GENERIC AND BRANDED

3.1.4.1. BRANDED

3.1.4.2. GENERIC

3.2. DIAGNOSTIC TYPE

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – NORTH AMERICA

4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2. COUNTRY ANALYSIS

4.2.1. THE UNITED STATES

4.2.2. CANADA

5.    COMPANY PROFILES

5.1. ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER

5.5. BIOGEN

5.6. COGNOPTIX

5.7. DIAGENIC ASA

5.8. ROCHE

5.9. GE HEALTHCARE

5.10. MERCK

5.11. JOHNSON & JOHNSON

5.12. PIRAMAL ENTERPRISES LTD.

5.13. SIEMENS HEALTHINEERS AG

5.14. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.    RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

           

            

List of table

TABLE 1        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 2        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($ MILLION)

TABLE 3        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($ MILLION)

TABLE 4        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 ($ MILLION)

TABLE 5        NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

TABLE 6        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 7        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

            

List of Figures

FIGURE 1      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 2      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 3      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)

FIGURE 4      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)

FIGURE 5      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)

FIGURE 6      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($ MILLION)

FIGURE 7      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)

FIGURE 8      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 ($ MILLION)

FIGURE 9      NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 ($ MILLION)

FIGURE 10   NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

FIGURE 11   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)

FIGURE 12   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 13   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)

FIGURE 14   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)

FIGURE 15   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 16   NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)

FIGURE 17   THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 18   CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;